BioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it compare to its rivals? We will compare BioLargo to similar businesses based on the strength of its analyst recommendations, risk, dividends, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares BioLargo and its rivals revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.00 |
BioLargo Competitors | $6.63 billion | $206.77 million | 67.66 |
BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1274 | 1591 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 4.94%. Given BioLargo’s rivals higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its rivals.
Volatility and Risk
BioLargo has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.78, indicating that their average share price is 78% more volatile than the S&P 500.
Institutional & Insider Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Summary
BioLargo rivals beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.